Alrushaid S, Zhao Y, Sayre CL, et al. Mechanistically elucidating the in vitro safety and efficacy of a novel doxorubicin derivative [published correction appears in Drug Deliv Transl Res. 2018 Oct;8(5):1592]. Drug Deliv Transl Res. 2017;7(4):582-597.
Andergassen, D., Rinn, J.L. From genotype to phenotype: genetics of mammalian long non-coding RNAs in vivo. Nat Rev Genet (2021).
Angeli D, Salvi S, Tedaldi G. Genetic Predisposition to Breast and Ovarian Cancers:
How Many and Which Genes to Test?. Int J Mol Sci. 2020;21(3):1128.
An J, Peng C, Tang H, Liu X, Peng F. New Advances in the Research of Resistance to Neoadjuvant Chemotherapy in Breast Cancer. Int J Mol Sci. 2021;22(17):9644.
Arun G, Diermeier SD, Spector DL. Therapeutic Targeting of Long Non-Coding RNAs in Cancer. Trends Mol Med. 2018;24(3):257-277.
Ashrafizaveh S, Ashrafizadeh M, Zarrabi A, Husmandi K, Zabolian A, Shahinozzaman M, Aref A.R, Hamblin M.R, Nabavi N, Crea F, Wang Y, Ahn K.S. Long non-coding RNAs in the doxorubicin resistance of cancer cells. Cancer Lett. (2021)
Azam, S., Lange, T., Huynh, S. et al. Hormone replacement therapy, mammographic density, and breast cancer risk: a cohort study. Cancer Causes Control 29, 495–505 (2018).
Baguley B.C. (2010) Multidrug Resistance in Cancer. In: Zhou J. (eds) Multi-Drug Resistance in Cancer. Methods in Molecular Biology (Methods and Protocols), vol 596.
Humana Press.
Ban KA, Godellas CV. Epidemiology of breast cancer. Surg Oncol Clin N Am. 2014 Jul;23(3):409-22
Barth DA, Juracek J, Slaby O, Pichler M, Calin GA. lncRNA and Mechanisms of Drug Resistance in Cancers of the Genitourinary System. Cancers (Basel). 2020;12(8):2148.
Brannan, C. I., Dees, E. C., Ingram, R. S. & Tilghman, S. M. The product of the H19 gene may function as an RNA. Mol. Cell. Biol. 10, 28–36 (1990).
Brenner DJ, Doll R, Goodhead DT, Hall EJ, Land CE, Little JB, Lubin JH, Preston DL, Preston RJ, Puskin JS, Ron E, Sachs RK, Samet JM, Setlow RB, Zaider M. Cancer risks attributable to low doses of ionizing radiation: assessing what we really know. Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):13761-6.
Brody JG, Rudel RA. Environmental Pollutants and Breast Cancer. Environmental Health Perspectives 2003; 111(8): 1007-1019.
Bond CS, Fox AH. Paraspeckles: nuclear bodies built on long noncoding RNA. J Cell Biol. 2009;186(5):637-644.
Bukowski K, Kciuk M, Kontek R. Mechanisms of Multidrug Resistance in Cancer Chemotherapy. International Journal of Molecular Sciences. 2020; 21(9):3233.
Cabili MN, Trapnell C, Goff L, et al. Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses. Genes Dev.
2011;25(18):1915-1927.
Carvalho C, Santos RX, Cardoso S, Correia S, Oliveira PJ, Santos MS, Moreira PI.
Doxorubicin: the good, the bad and the ugly effect. Curr Med Chem. 2009;16(25):3267-85.
Cerk S, Schwarzenbacher D, Adiprasito JB, et al. Current Status of Long Non-Coding RNAs in Human Breast Cancer. Int J Mol Sci. 2016;17(9):1485.
Cheang, M. C. U. et al. Defining breast cancer intrinsic subtypes by quantitative receptor expression. Oncologist 20, 474–482 (2015).
Chi Y, Wang D, Wang J, Yu W, Yang J. Long Non-Coding RNA in the Pathogenesis of Cancers. Cells. 2019;8(9):1015.
Choudhry H, Albukhari A, Morotti M, Haider S, Moralli D, Smythies J, Schödel J, Green CM, Camps C, Buffa F, Ratcliffe P, Ragoussis J, Harris AL, Mole DR. Tumor hypoxia induces nuclear paraspeckle formation through HIF-2α dependent transcriptional activation of NEAT1 leading to cancer cell survival. Oncogene. 2015 Aug 20;34(34):4482-90.
Cogill SB, Wang L. Co-expression Network Analysis of Human lncRNAs and Cancer Genes. Cancer Inform. 2014;13(Suppl 5):49-59.
Coignard J, Lush M, Beesley J, et al. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers [published correction appears in Nat Commun. 2021 May 14;12(1):2986]. Nat Commun. 2021;12(1):1078.
Collaborative Group on Hormonal Factors in Breast Cancer. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. Lancet Oncol. 2012 Nov;13(11):1141-51.
Coyle YM. The effect of environment on breast cancer risk. Breast Cancer Res Treat.
2004 Apr;84(3):273-88.
Crudele, F., Bianchi, N., Reali, E. et al. The network of non-coding RNAs and their molecular targets in breast cancer. Mol Cancer 19, 61 (2020).
Dass SA, Tan KL, Selva Rajan R, et al. Triple Negative Breast Cancer: A Review of Present and Future Diagnostic Modalities. Medicina (Kaunas). 2021;57(1):62.
Deng, H., Zhang, J., Shi, J. et al. Role of long non-coding RNA in tumor drug resistance.
Tumor Biol. 37, 11623–11631 (2016).
Deniz, E., Erman, B. Long noncoding RNA (lincRNA), a new paradigm in gene expression control. Funct Integr Genomics 17, 135–143 (2017).
DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, Alteri R, Robbins AS, Jemal A. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin.
2014 Jul-Aug;64(4):252-71
Dieci MV, Orvieto E, Dominici M, Conte P, Guarneri V. Rare breast cancer subtypes:
histological, molecular, and clinical peculiarities. Oncologist. 2014;19(8):805-813.
Ding S, Wu J, Lin C, et al. Evaluation of the Incorporation of Recurrence Score into the American Joint Committee on Cancer Eighth Edition Staging System in Patients with T1-2N0M0, Estrogen Receptor-Positive, Human Epidermal Growth Receptor 2-Negative Invasive Breast Cancer: A Population-Based Analysis. Oncologist. 2019;24(11):e1014-e1023.
Dong P, Xiong Y, Yue J, et al. Long Non-coding RNA NEAT1: A Novel Target for Diagnosis and Therapy in Human Tumors. Front Genet. 2018;9:471.
Edefonti V, Randi G, La Vecchia C, et al. Dietary patterns and breast cancer: a review with focus on methodological issues. Nutr Rev 2009; 67: 297-314.
Espie M, Lalloum M, Coussy F. Epidemiology and risk factors of breast cancer. Soins;
la revue de reference infirmiere 2013; 776:22-4.
Edwards SL, French JD. NEAT1 isoform expression in breast cancer. Non-coding RNA Investig 2020;4:4.
Fabbri A, Carcangiu ML, Carbone A. Histological classification of breast cancer. Breast Cancer: Springer; 2008. p. 3-14.
Farmakoloji, Anabilim & Yurtsever, A. & Tiftik, R. (2021). KEMOTERAPİYE DİRENÇLİ MEME KANSERİ TEDAVİSİNDE YENİ UFUKLARA DOĞRU: UZUN KODLAMAYAN RNA'LAR.
Feigelson HS, Jonas CR, Teras LR, Thun MJ, Calle EE. Weight gain, body mass index, hormone replacement therapy, and postmenopausal breast cancer in a large prospective study. Cancer Epidemiol Biomarkers Prev. 2004 Feb;13(2):220-4.
Feng Y, Spezia M, Huang S, et al. Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis.
Genes Dis. 2018;5(2):77-106.
Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013 Apr;49(6):1374-403.
Fragomeni SM, Sciallis A, Jeruss JS. Molecular Subtypes and Local-Regional Control of Breast Cancer. Surg Oncol Clin N Am. 2018;27(1):95-120.
Freudenheim JL. Alcohol's Effects on Breast Cancer in Women. Alcohol Res.
2020;40(2):11.
Fridrichova I, Zmetakova I. MicroRNAs Contribute to Breast Cancer Invasiveness. Cells.
2019;8(11):1361.
Gage M, Wattendorf D, Henry LR. Translational advances regarding hereditary breast cancer syndromes. J Surg Oncol. 2012 Apr 1;105(5):444-51.
Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol. 2007;608:1-22.
Gullerova M. Long Non-coding RNA. Genomic Elements in Health, Disease and Evolution. 2015;83-108.
Guo Y, Zhang H, Xie D, Hu X, Song R, Zhu L. Non-coding RNA NEAT1/miR-214-3p contribute to doxorubicin resistance of urothelial bladder cancer preliminary through the Wnt/β-catenin pathway. Cancer Manag Res. 2018;10:4371-4380.
Gupta, R., Shah, N., Wang, K. et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 464, 1071–1076 (2010).
Hamdi Y, Soucy P, Adoue V, et al. Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21. Oncotarget. 2016;7(49):80140-80163.
Hauptman N, Glavač D. Long Non-Coding RNA in Cancer. International Journal of Molecular Sciences. 2013; 14(3):4655-4669.
He, J., Zhu, S., Liang, X. et al. LncRNA as a multifunctional regulator in cancer multi-drug resistance. Mol Biol Rep 48, 1–15 (2021).
Heath AK, Muller DC, van den Brandt PA, et al. Nutrient-wide association study of 92 foods and nutrients and breast cancer risk. Breast Cancer Res. 2020;22(1):5.
Heesch S, Iterson M, Jacobi J, et al. Extensive localization of long noncoding RNAs to the cytosol and mono- and polyribosomal complexes. Genome Biol. 2014;15(1):R6.
Helleday, T., Petermann, E., Lundin, C. et al. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 8, 193–204 (2008).
Henderson TO, Amsterdam A, Bhatia S, Hudson MM, Meadows AT, Neglia JP, Diller LR, Constine LS, Smith RA, Mahoney MC, Morris EA, Montgomery LL, Landier W, Smith SM, Robison LL, Oeffinger KC. Systematic review: surveillance for breast cancer in women treated with chest radiation for childhood, adolescent, or young adult cancer.
Ann Intern Med. 2010 Apr 6;152(7):444-55; W144-54.
Hindorff, L.A., et al., Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proceedings of the National Academy of Sciences, 2009. 106(23): 9362-9367.
Hortobagyi GN, de la Garza Salazar J, Pritchard K, Amadori D, Haidinger R, Hudis CA, Khaled H, Liu MC, Martin M, Namer M, O'Shaughnessy JA, Shen ZZ, Albain KS;
ABREAST Investigators. The global breast cancer burden: variations in epidemiology and survival. Clin Breast Cancer. 2005. Dec;6(5):391-401.
Hou Y, Zhang R and Sun X (2019) Enhancer LncRNAs Influence Chromatin Interactions in Different Ways. Front. Genet. 10:936.
Howell A, Anderson AS, Clarke RB, et al. Risk determination and prevention of breast cancer. Breast Cancer Res. 2014;16(5):446.
Hu G, Niu F, Humburg BA, et al. Molecular mechanisms of long noncoding RNAs and their role in disease pathogenesis. Oncotarget. 2018;9(26):18648-18663.
Hutchinson, J.N., Ensminger, A.W., Clemson, C.M. et al. A screen for nuclear transcripts identifies two linked noncoding RNAs associated with SC35 splicing domains. BMC Genomics 8, 39 (2007).
Jiang X, Zhou Y, Sun AJ, Xue JL. NEAT1 contributes to breast cancer progression through modulating miR-448 and ZEB1. J Cell Physiol. 2018 Nov;233(11):8558-8566.
Jung S, Wang M, Anderson K, et al. Alcohol consumption and breast cancer risk by estrogen receptor status: in a pooled analysis of 20 studies. Int J Epidemiol.
2016;45(3):916-928.
Kasiappan R, Rajarajan D. Role of MicroRNA Regulation in Obesity-Associated Breast Cancer: Nutritional Perspectives. Adv Nutr. 2017;8(6):868-888.
Katsuta E, Yan L, Nagahashi M, et al. Doxorubicin effect is enhanced by sphingosine-1-phosphate signaling antagonist in breast cancer. J Surg Res. 2017;219:202-213.
Ke H, Zhao L, Feng X, et al. NEAT1 is Required for Survival of Breast Cancer Cells Through FUS and miR-548. Gene Regul Syst Bio. 2016;10(Suppl 1):11-17.
Kimberly H. Allison, MD, Molecular Pathology of Breast Cancer: What a Pathologist Needs to Know, American Journal of Clinical Pathology, Volume 138, Issue 6, December 2012, Pages 770–780.
Kim TK, Hemberg M, Gray JM. Enhancer RNAs: a class of long noncoding RNAs synthesized at enhancers. Cold Spring Harb Perspect Biol. 2015;7(1):a018622.
Klec, C., Prinz, F. and Pichler, M. (2019), Involvement of the long noncoding RNA NEAT1 in carcinogenesis. Mol Oncol, 13: 46-60.
Li, M.D., Cheng, R., Ma, J.Z. and Swan, G.E. (2003), A meta-analysis of estimated genetic and environmental effects on smoking behavior in male and female adult twins.
Addiction, 98: 23-31.
Lin Y, Schmidt BF, Bruchez MP, McManus CJ. Structural analyses of NEAT1 lncRNAs suggest long-range RNA interactions that may contribute to paraspeckle architecture.
Nucleic Acids Res. 2018 Apr 20;46(7):3742-3752.
Liu K, Gao L, Ma X, et al. Long non-coding RNAs regulate drug resistance in cancer.
Mol Cancer. 2020;19(1):54.
Liu X, Yao W, Xiong H, Li Q, Li Y. LncRNA NEAT1 accelerates breast cancer progression through regulating miR-410-3p/ CCND1 axis. Cancer Biomark. 2020;29(2):277-290.
Liu Y, Nguyen N, Colditz GA. Links between alcohol consumption and breast cancer: a look at the evidence. Womens Health (Lond). 2015;11(1):65-77.
Lof M, Weiderpass E. Impact of diet on breast cancer risk. Curr Opin Obstet Gynecol 2009; 21: 80-85.
Lofterød T, Frydenberg H, Flote V, et al. Exploring the effects of lifestyle on breast cancer risk, age at diagnosis, and survival: the EBBA-Life study. Breast Cancer Res Treat.
2020;182(1):215-227.
Łukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanisławek A. Breast Cancer-Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies-An Updated Review. Cancers (Basel). 2021;13(17):4287.
Ma H, Hill CK, Bernstein L, Ursin G. Low-dose medical radiation exposure and breast cancer risk in women under age 50 years overall and by estrogen and progesterone receptor status: results from a case-control and a case-case comparison. Breast Cancer Res Treat. 2008 May;109(1):77-90. 9
Macfarlane LA, Murphy PR. MicroRNA: Biogenesis, Function and Role in Cancer. Curr Genomics. 2010;11(7):537-561.
Mansoori B, Mohammadi A, Davudian S, Shirjang S, Baradaran B. The Different Mechanisms of Cancer Drug Resistance: A Brief Review. Adv Pharm Bull.
2017;7(3):339-348.
Marjoribanks J, Farquhar C, Roberts H, Lethaby A, Lee J. Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev. 2017 Jan 17;1(1):CD004143.
Marzbani B, Nazari J, Najafi F, et al. Dietary patterns, nutrition, and risk of breast cancer:
a case-control study in the west of Iran. Epidemiol Health. 2019;41:e2019003.
Mian M, Tinelli M, DE March E, Turri G, Meneghini V, Pescosta N, Berno T ve ark.
Bortezomib, Thalidomide and Lenalidomide: Have They Really Changed the Outcome of Multiple Myeloma? Anticancer Res. 2016;36(3):1059-65
Momenimovahed Z, Salehiniya H. Epidemiological characteristics of and risk factors for breast cancer in the world. Breast Cancer (Dove Med Press). 2019;11:151-164.
Mukama T, Fallah M, Brenner H, et al. Risk of invasive breast cancer in relatives of patients with breast carcinoma in situ: a prospective cohort study. BMC Med.
2020;18(1):295.
Nakagawa S, Naganuma T, Shioi G, Hirose T. Paraspeckles are subpopulation-specific nuclear bodies that are not essential in mice. J Cell Biol. 2011 Apr 4;193(1):31-9.
Newman B, Austin MA, Lee M, King MC. Inheritance of human breast cancer: evidence for autosomal dominant transmission in high-risk families. Proc Natl Acad Sci U S A.
1988 May;85(9):3044-8.
F P Perera, A Estabrook, A Hewer, K Channing, A Rundle, L A Mooney, R Whyatt and D H Phillips, Carcinogen-DNA adducts in human breast tissue. Cancer Epidemiol Biomarkers Prev April 1 1995 (4) (3) 233-238;
Petri BJ, Klinge CM. Regulation of breast cancer metastasis signaling by miRNAs.
Cancer Metastasis Rev. 2020;39(3):837-886.
Picon-Ruiz M, Morata-Tarifa C, Valle-Goffin JJ, Friedman ER, Slingerland JM. Obesity and adverse breast cancer risk and outcome: Mechanistic insights and strategies for intervention. CA Cancer J Clin. 2017;67(5):378-397.
Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X, Perou CM.
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010;12(5):R68.
Prensner JR, Chinnaiyan AM. The emergence of lncRNAs in cancer biology. Cancer Discov. 2011;1(5):391-407.
Rahman MM, Brane AC, Tollefsbol TO. MicroRNAs and Epigenetics Strategies to Reverse Breast Cancer. Cells. 2019;8(10):1214.
Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies.
Lancet. 2008 Feb 16;371(9612):569-78
Romano G, Saviana M, Le P, et al. Non-Coding RNA Editing in Cancer Pathogenesis.
Cancers (Basel). 2020;12(7):1845.
Rosen PP, Maia DM. Rosen's breast pathology. Archives of Pathology and Laboratory Medicine. 1998;122(5):480.
Salaroglio IC, Gazzano E, Abdullrahman A, et al. Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer. J Exp Clin Cancer Res. 2018;37(1):286.
Schoemaker MJ, Nichols HB, Wright LB, et al. Adult weight change and premenopausal breast cancer risk: A prospective pooled analysis of data from 628,463 women. Int J Cancer. 2020;147(5):1306-1314.
Sharma GN, Dave R, Sanadya J, Sharma P, Sharma KK. Various types and management of breast cancer: an overview. J Adv Pharm Technol Res. 2010;1(2):109-126.
Shin VY, Chen J, Cheuk IW, et al. Long non-coding RNA NEAT1 confers oncogenic role in triple-negative breast cancer through modulating chemoresistance and cancer stemness. Cell Death Dis. 2019;10(4):270.
Siddeek B, Mauduit C, Chehade H, et al. Long-term impact of maternal high-fat diet on offspring cardiac health: role of micro-RNA biogenesis. Cell Death Discov. 2019;5:71.
Singh, N. Role of mammalian long non-coding RNAs in normal and neuro oncological disorders. Elsevier. 113, 5, (2021).
Slack FJ, Chinnaiyan AM. The Role of Non-coding RNAs in Oncology. Cell.
2019;179(5):1033-1055.
Sponer J, Bussi G, Krepl M, Banáš P, Bottaro S, Cunha RA, Gil-Ley A, Pinamonti G, Poblete S, Jurečka P, Walter NG, Otyepka M. RNA Structural Dynamics As Captured by Molecular Simulations: A Comprehensive Overview. Chem Rev. 2018 Apr 25;118(8):4177-4338.
Standaert L, Adriaens C, Radaelli E, Van Keymeulen A, Blanpain C, Hirose T, Nakagawa S, Marine JC. The long noncoding RNA Neat1 is required for mammary gland development and lactation. RNA. 2014 Dec;20(12):1844-9
Sun M, Kraus WL. From discovery to function: the expanding roles of long noncoding RNAs in physiology and disease. Endocr Rev. 2015;36(1):25-64.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249
Şen, S. , Aygin, D. "Meme Kanserinin Etiyolojisinde Çevresel Karsinojenlerin Rolü".
Sakarya Tıp Dergisi 4 (2014 ): 109-114
Talib WH, Alsayed AR, Barakat M, Abu-Taha MI, Mahmod AI. Targeting Drug Chemo-Resistance in Cancer Using Natural Products. Biomedicines. 2021;9(10):1353.
The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 490, 61–70 (2012).
Thorn CF, Oshiro C, Marsh S, et al. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics. 2011;21(7):440-446.
Turgut Cosan D, Yagcı E, Kurt H. 2018, Extending Lines from Epigenetic to Cancer:
Long Non-coding RNAs, Osmangazi Journal of Medicine, 40(3):114-121.
Uszczynska-Ratajczak B, Lagarde J, Frankish A, Guigó R, Johnson R. Towards a complete map of the human long non-coding RNA transcriptome. Nat Rev Genet.
2018;19(9):535-548.
Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases. BMJ. 2020;371:m3873.
Vuong, D., Simpson, P.T., Green, B. et al. Molecular classification of breast cancer.
Virchows Arch 465, 1–14 (2014)
Wen HY, Brogi E. Lobular Carcinoma In Situ. Surg Pathol Clin. 2018;11(1):123-145.
Web_1 The World Health Organization internet sitesi. https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death. (Erişim Tarihi: 23.11.2021).
Web_2 Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A.
(2018), Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68:
394-424. Erişim adresi:
https://acsjournals.onlinelibrary.wiley.com/doi/full/10.3322/caac.21492. (Son güncelleme tarihi: 2021, Erişim Tarihi: 23.11.2021).
Web_3 Türkiye Kanser İstatistikleri, 2020.
https://www.saglikaktuel.com/d/file/38131,memekanskr20200720pdf.pdf (Erişim Tarihi:
23.11.2021).
Web_4 İmaginis internet sitesi, https://www.imaginis.com/breast-cancer-diagnosis/staging-and-survival-rates-of-breast-cancer-3?r (Erişim Tarihi: 23.11.2021).
Web_5 Türkiye Kanser İstatistikleri, 2017.
https://hsgm.saglik.gov.tr/depo/birimler/kanser-db/istatistik/Turkiye_Kanser_Istatistikleri_2017.pdf (Erişim Tarihi: 23.11.2021).